2020-09-04
FDA Approves pralsetinib for RET+ Lung Cancer
The FDA has approved pralsetinib(formerly known as BLU-667; GAVRETO™) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, September 4, 2020
Contact

Address

Office: Philadelphia, US

Office: Building 10-1, No.2 Jingyuan North Street, BDA, Beijing, China

Tel

+1-484-222-1342 +86-10-67860673

Mobile Mode
Copyright © 2022 All Rights Reserved Applied Pharmaceutical Science
Terms of Use

Loading...

Privacy policy

Loading...